Combination of anlotinib and albumin-bound paclitaxel in 2nd line and above treatment of advanced gastric cancer: A retrospective study

Figure 3 Changes in the proportion of other immune cells (CD4⁺, CD8⁺, and NK⁺ cells) in peripheral blood before and after treatment with anlotinib combined with nab-ptx in patients with advanced gastric cancer receiving second-line or higher treatment. The changes in the proportions of CD4⁺, CD8⁺, and NK⁺ cells in peripheral blood before and after treatment, respectively. A: CD4⁺; B: CD8⁺; C: NK⁺.